Targeting
tumor cells metabolism

Our first lead candidate, the ironomycin, is a proprietary chemical molecule, highly active in vitro and in vivo, which accumulates in lysosomes of persistent cancer cells  where it can sequester iron, disturbing then iron metabolism in the cell.

Eradicate cancer cells
escaping conventional treatment

SideROS aims to improve the conditions of patients affected by life-threatening diseases lacking of effective treatment.

SideROS promotes the development of innovative research on iron-targeting chemical compounds to target persistent cancer cells, refractory to conventional treatments and associated to metastasis and relapse.

Disturbing tumor cells metabolism, through specific inhibition of iron metabolism, is a novel targeted treatment

The role of iron is ubiquitous whatever the origin of cancer cells, suggesting that our small molecules can target various types of cancer.